VR Adviser’s Black Diamond Therapeutics BDTX Stock Holding History

VR Adviser’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-353,629	Closed	-$1.79M	–	39
2023 Q2	$1.79M	Buy	+353,629	New	+$722K	0.29%	27

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VR Adviser's BDTX Position: Q3 2023 in Review

VR Adviser sold out of Black Diamond Therapeutics (BDTX) in Q3 2023, closing a stake of 353,629 shares — an estimated $1.79M sold.

VR Adviser first reported a position in BDTX in Q2 2023 and held it in 1 quarter. The position peaked at $1.79M in Q2 2023. 73 funds tracked by Wall St. Rank hold BDTX as of Q3 2023.

VR Adviser reported no remaining Black Diamond Therapeutics position as of Q3 2023 after selling out during the quarter.
VR Adviser sold 353,629 Black Diamond Therapeutics shares in Q3 2023, an estimated $1.79M.
VR Adviser first reported a position in Black Diamond Therapeutics in Q2 2023 and held it in 1 quarter.
VR Adviser's Black Diamond Therapeutics position peaked at $1.79M in Q2 2023.
73 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2023.

Based on VR Adviser's 13F filing for Q3 2023, filed 14 Nov 2023.